Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers

BACKGROUND: The purpose of this study was to assess the efficacy and safety of biosimilar infliximab (IFX) CT-P13 in treating outpatients with inflammatory bowel disease (IBD) in Italian primary gastroenterology centers. METHODS: Consecutive IBD outpatients who completed the induction treatment were...

Descripción completa

Detalles Bibliográficos
Autores principales: Tursi, Antonio, Mocci, Giammarco, Faggiani, Roberto, Allegretta, Leonardo, Valle, Nicola Della, Forti, Giacomo, Franceschi, Marilisa, Ferronato, Antonio, Gallina, Sara, Larussa, Tiziana, Luzza, Francesco, Lorenzetti, Roberto, Penna, Antonio, Rodino, Stefano, Sebkova, Ladislava, Lauria, Angelo, Piergallini, Simona, Pranzo, Giuseppe, Ricciardelli, Cristina, Zampaletta, Costantino, Elisei, Walter, Picchio, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595921/
https://www.ncbi.nlm.nih.gov/pubmed/31263362
http://dx.doi.org/10.20524/aog.2019.0377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595921/
https://www.ncbi.nlm.nih.gov/pubmed/31263362
http://dx.doi.org/10.20524/aog.2019.0377

Ejemplares similares